[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.]

Kuznik, B I; Shapovalov, K G; Smolyakov, Y N; Lukyanov, S A; Tereshkov, P P; Kazantseva, L S; Linkova, N S

Kuznik, B I; Shapovalov, K G; Smolyakov, Y N; Lukyanov, S A; Tereshkov, P P; Kazantseva, L S; Linkova, N S.

Afiliação

Kuznik BI; Chita State Medical Academy, 39a Gorkogo str, Chita 672000, Russian Federation.
Shapovalov KG; Chita State Medical Academy, 39a Gorkogo str, Chita 672000, Russian Federation.
Smolyakov YN; Chita State Medical Academy, 39a Gorkogo str, Chita 672000, Russian Federation.
Lukyanov SA; Chita State Medical Academy, 39a Gorkogo str, Chita 672000, Russian Federation.
Tereshkov PP; Chita State Medical Academy, 39a Gorkogo str, Chita 672000, Russian Federation.
Kazantseva LS; Regional Clinical Infectious Diseases Hospital, 21 Truda str., Chita 672042, Russian Federation.
Linkova NS; Belgorod State National Research University, 85 Pobedy str, Belgorod 308015, Russian Federation.

Adv Gerontol ; 35(3): 368-374, 2022.

Article em Ru | MEDLINE | ID: mdl-36169363

Assuntos

Tratamento Farmacológico da COVID-19; Idoso; Anticorpos Monoclonais Humanizados; Coagulação Sanguínea; Humanos; Lactato Desidrogenases; Pessoa de Meia-Idade; Estudos Retrospectivos; SARS-CoV-2; Hormônios do Timo; Resultado do Tratamento

Palavras-chave

Thymalin; Tocilizumab; elderly; hemostasis; immunogenesis; middle aged; severe COVID-19

Buscar no Google

Imprimir

XML

PubMed Links

Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: Ru Ano de publicação: 2022 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links